Search in site
Neurostimulation is a long standing therapy with years of accumulated experience and demonstrated effectiveness. Now, physicians and patients are ready for a new product that will unlock the enormous potential of the therapy.
RENOVA™ - for the treatment of patients with Overactive Bladder and associated symptoms of urinary urgency and frequency, with or without urge incontinence.
A miniature implant which is battery-less and wirelessly powered and delivers targeted electric stimulation to the nerve
Wirelessly powering the Stimulator
Enabling the clinician full control of stimulation parameters to optimize the therapy for the patient
Enabling patients control of their treatment.
The Bluewind Medical neurostimulator is significantly smaller than conventional devices. Advanced technologies allow the transformation to a minimally invasive procedure
No wires tunneled under the skin thus avoiding lead migration or fracture
Lifelong neurostimulator - no need for repeated surgeries to replace the depleted battery
The BlueWind Medical device incorporates the latest technological advancements including Tonic, Burst and High-Frequency stimulation and more
The easier procedure and smaller implant support a growing number of indications and increased access to therapy
MR conditional for static magnetic field of 1.5 and 3 Tesla
The opportunity for growth in the $700 Million Overactive Bladder (OAB) Neurostimulation market is vast.
14.3 Million patients in the US suffer from OAB and are refractory to medication, of which only 150,000 patients are treated with neurostimulation. This is primarily due to the complexity, invasiveness, complications and cost of existing solutions. BlueWind Medical is poised to capitalize on this market need, leveraging its technological advantages and unique design to treat many more patients.